<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04653493</url>
  </required_header>
  <id_info>
    <org_study_id>CD19 CAR T Cells for R/R ALL</org_study_id>
    <nct_id>NCT04653493</nct_id>
  </id_info>
  <brief_title>CD19 Targeted CAR T Cell Therapy in Patients With Relapsed/ Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)</brief_title>
  <official_title>Phase I Clinical Trial Evaluating Safety of CD19 CAR-T Cells in Patients With Relapsed or Refractory Acute B-cell Lymphoblastic Leukemia (R/R B-ALL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sabz Biomedicals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gene Therapy Research Center, Shariati Hospital, Tehran University of Medical Sciences, Iran</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Research Institute for Oncology- Hematology and Cell Therapy (RIOHCT), Tehran University of Medical Sciences, Iran</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sabz Biomedicals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-arm, open-label, phase I study (safety and dose escalation) of autologous&#xD;
      Chimeric Antigen Receptor (CAR) T-cells targeting CD19 in patients with relapsed/refractory B&#xD;
      cell acute lymphoblastic leukemia (ALL).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this single-center, open-label, nonrandomized, no control, prospective clinical trial,&#xD;
      pediatric or adolescent/young adult patients with CD19+ relapsed or refractory B cell acute&#xD;
      lymphoblastic leukemia (R/R B-ALL) will be enrolled.&#xD;
&#xD;
      Eligible patients will receive CAR T product intravenously as a single or split dose&#xD;
      following pre-conditioning by a lymphodepleting chemotherapeutic regimen and will then enter&#xD;
      a 30-day follow-up period to monitor adverse events using the NCI CTCAE (version 5.0).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">August 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) and Dose-limiting Toxicities (DLT) of CD19 CAR-T cells</measure>
    <time_frame>Within 30 days after the last dose of CD19 CAR-T cells</time_frame>
    <description>Patients will be continually assessed for unexpected adverse events using the NCI CTCAE (version 5.0) or unexpected early mortality 30 days post-infusion.&#xD;
The primary objectives for the Phase I study portion are to determine the maximum tolerated dose (MTD) and characterize the safety profile and dose-limiting toxicities (DLTs) of treatment with CD19 CAR-T cells in pediatric, adolescent and young adult patient's ≤ 25 years of age, with relapsed/refractory CD19+ ALL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients who achieve complete morphological remission</measure>
    <time_frame>Within 30 days post CD19 CAR-T cells</time_frame>
    <description>Number of patients who achieve complete morphological remission (Complete Response (CR) or Complete Response with Incomplete count recovery (CRi) in the bone marrow)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Relapsed B Cell Acute Lymphoblastic Leukemia (ALL)</condition>
  <condition>Refractory B Cell Acute Lymphoblastic Leukemia (ALL)</condition>
  <arm_group>
    <arm_group_label>CD19 CAR-T cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pediatric or adolescent/young adult patients with CD19+ relapsed or refractory B cell acute lymphoblastic leukemia (R/R B-ALL)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CD19 CAR engineered autologous T-cells</intervention_name>
    <description>Given IV&#xD;
Following preconditioning with lymphodepleting chemotherapy (cyclophosphamide and fludarabine) patients will be treated with CD19 Chimeric Antigen Receptor (CAR) T cells as a single or split dose (day 0, 1 and 2, CAR cells will be intravenously infused at the 10%, 30% and 60% ratio respectively). Dosing of CD19 CAR-T cells will follow a dose-escalation schema, with dose changes based on dose-limiting toxicities.</description>
    <arm_group_label>CD19 CAR-T cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>CD19 CAR-T cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>CD19 CAR-T cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesna</intervention_name>
    <description>Given IV</description>
    <arm_group_label>CD19 CAR-T cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        CD19+ ALL patients with any of the following:&#xD;
&#xD;
          1. Relapsed or Refractory CD19 positive B-cell acute lymphoblastic leukemia (R/R B-ALL)&#xD;
             A. Primary refractory disease despite at least 2 cycles of an intensive chemotherapy&#xD;
             regimen designed to induce remission B. Refractory disease despite salvage therapy C.&#xD;
             2nd or greater relapse D. Any relapse after allogeneic hematopoietic stem cell&#xD;
             transplantation&#xD;
&#xD;
          2. Informed consent explained to and signed by patient/parents or legal guardian.&#xD;
&#xD;
          3. The Karnofsky (age ≥10 years)/Lansky (age &lt;10 years) performance status score over 50&#xD;
             points.&#xD;
&#xD;
          4. Expected to survive for more than 3 months.&#xD;
&#xD;
          5. Patients with a history of prior allogeneic hematopoietic stem cell transplant (HSCT)&#xD;
             must be at least 3 months from HSCT at the time of CD19 CAR-T cells infusion and also&#xD;
             have not received a donor lymphocyte infusion (DLI) within the 28 days prior to&#xD;
             apheresis.&#xD;
&#xD;
          6. Important organ function is satisfied: Heart ultrasound indicates cardiac ejection&#xD;
             fraction ≥ 50%, no obvious abnormality in ECG; Adequate pulmonary function defined as&#xD;
             forced vital capacity (FVC) ≥ 50% of predicted value; or pulse oximetry ≥ 92% on room&#xD;
             air if the patient is unable to perform pulmonary function testing; creatinine&#xD;
             clearance calculated by Cockcroft-Gault formula ≥ 50 ml/min/1.73m2; Alanine&#xD;
             aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 5 times the upper limit&#xD;
             of normal for age; Total Bilirubin ≤ 3 times the upper limit of normal for age.&#xD;
&#xD;
          7. Absolute lymphocyte count ≥ 0.5 x 10⁹/L.&#xD;
&#xD;
          8. Hemoglobin ≥ 8 g/dl (can be transfused).&#xD;
&#xD;
          9. Platelet count ≥ 20,000/μL (can be transfused).&#xD;
&#xD;
         10. Meets eligibility criteria to undergo autologous apheresis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Isolated extra-medullary disease relapse.&#xD;
&#xD;
          2. Active CNS involvement of ALL (CNS Grade 3 per National Comprehensive Cancer Network&#xD;
             guidelines).&#xD;
&#xD;
          3. Severe, uncontrolled bacterial, fungal or viral infections (Active hepatitis B or C,&#xD;
             history of HIV infection)&#xD;
&#xD;
          4. Pre-existing significant neurological disorder.&#xD;
&#xD;
          5. Active significant acute graft versus host disease (GVHD) or moderate/severe chronic&#xD;
             GVHD requiring systemic steroids or other immunosuppressants within 4 weeks of&#xD;
             enrolment.&#xD;
&#xD;
          6. Pregnant or lactating female.&#xD;
&#xD;
          7. The patient did not agree to use effective contraception during the treatment period&#xD;
             and for the following 1 year.&#xD;
&#xD;
          8. A history of other malignant tumors.&#xD;
&#xD;
          9. Receiving systemic steroids therapy exceeding the equivalent of 0.5 mg/ kg/day of&#xD;
             methylprednisolone, in the 7 days prior to CAR T-cell infusion&#xD;
&#xD;
         10. Receiving systemic immunosuppressive therapy in the 14 days prior to CAR T-cell&#xD;
             infusion&#xD;
&#xD;
         11. Receiving intrathecal chemotherapy in the 7 days prior to CAR T-cell infusion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tahereh Rostami, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Institute for Oncology- Hematology and Cell Therapy (RIOHCT), Tehran University of Medical Sciences, Tehran, Iran</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Naser Ahmadbeigi, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Gene Therapy Research Center, Shariati hospital, Tehran University of Medical Sciences, Tehran, Iran</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tahereh Rostami, M.D</last_name>
    <phone>+9821-88004140</phone>
    <email>trostami@sina.tums.ac.ir</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Naser Ahmadbeigi, PhD</last_name>
    <phone>+9821-82415103</phone>
    <email>n-ahmadbeigi@sina.tums.ac.ir</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gene therapy research center, Shariati hospital, Tehran university of medical sciences, Iran</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Naser Ahmadbeigi, Phd</last_name>
      <phone>+9821-82415103</phone>
      <email>n-ahmadbeigi@sina.tums.ac.ir</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Institute for Oncology- Hematology and Cell Therapy (RIOHCT), Tehran University of Medical Sciences</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Tahereh Rostami, M.D</last_name>
      <phone>+982188004140</phone>
      <email>trostami@sina.tums.ac.ir</email>
    </contact>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 22, 2020</study_first_submitted>
  <study_first_submitted_qc>November 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2020</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CD19+ B-cell Acute Lymphoblastic Leukemia</keyword>
  <keyword>CAR T cell</keyword>
  <keyword>Relapsed/Refractory B cell acute lymphoblastic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

